755-nm Picosecond vs. Nanosecond Alexandrite Lasers for Tattoo Removal: A Randomized, Split-Tattoo Clinical Trial.

Summary

In a randomized split-tattoo trial (n=30), 755-nm picosecond alexandrite laser achieved superior clearance versus nanosecond with higher rates of satisfactory and complete clearance, lower pain, and fewer acute complications, albeit with increased hyperpigmentation. Findings support PSAL as a first-line modality for black/blue tattoos, with parameter optimization to mitigate pigmentary risk.

Key Findings

• Higher clearance with PSAL vs NSAL (VAS median 8 [IQR 6–9] vs 5 [2.75–6.25]; p<0.0001).
• Satisfactory clearance (VAS ≥7) in 73.3% with PSAL vs 23.3% with NSAL (p=0.0003); complete clearance 10% vs 0%.
• Lower pain with PSAL (p=0.023) and fewer acute events: bleeding 2% vs 8% (p=0.031), blistering 7.33% vs 15.33% (p=0.044), crusting 7.33% vs 15.33% (p=0.044).
• Higher hyperpigmentation with PSAL (21.33% vs 12%; p=0.043).

Clinical Implications

Prefer 755-nm PSAL for black/blue tattoo removal to achieve higher clearance with less pain and fewer acute reactions; counsel patients on higher hyperpigmentation risk and tailor pulse parameters and intervals, especially in darker skin types.

Limitations

• Modest sample size (n=30) and 6-month follow-up limit long-term generalizability.
• Restricted to black/blue tattoos; pigmentation sequelae higher with PSAL.

Future Directions

Evaluate longer-term recurrence/clearance, optimize pulse parameters to reduce hyperpigmentation, and extend to multicolor tattoos and diverse Fitzpatrick skin types.